Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

未开盘 04-23 16:00:00 EDT

41.84

+0.77

+1.87%

盘后41.84

+0.000.00%

16:54 EDT

最高42.25	最低40.90	成交量63.12万
今开41.28	昨收41.07	日振幅3.29%
总市值60.98亿	流通市值60.47亿	总股本1.46亿
成交额2,649万	换手率0.44%	流通股本1.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":41.84,"timestamp":1713902400000,"preClose":41.07,"halted":0,"volume":631237,"hourTrading":{"tag":"盘后","latestPrice":41.84,"preClose":41.84,"latestTime":"16:54 EDT","volume":18942,"amount":792533.15,"timestamp":1713905644758},"delay":0,"floatShares":144524217,"shares":145751797,"eps":-2.558041,"marketStatus":"未开盘","marketStatusCode":0,"change":0.77,"latestTime":"04-23 16:00:00 EDT","open":41.28,"high":42.25,"low":40.9,"amount":26492357.878572,"amplitude":0.032871,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.558041,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1713945600000},"adr":0,"adjPreClose":41.07,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":41.84,"preClose":41.84,"latestTime":"16:54 EDT","volume":18942,"amount":792533.15,"timestamp":1713905644758},"volumeRatio":0.654871},"requestUrl":"/m/hq/s/IONS?invite=TIGER025","defaultTab":"news","newsList":[{"id":"2426161950","title":"Needham：重申Ionis Pharmaceuticals(IONS.US)评级，由买入调整至买入评级, 目标价60.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426161950","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426161950?lang=zh_cn&edition=full","pubTime":"2024-04-09 18:45","pubTimestamp":1712659533,"startTime":"0","endTime":"0","summary":"Needham：重申Ionis Pharmaceuticals(IONS.US)评级，由买入调整至买入评级, 目标价60.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091845348b031876&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091845348b031876&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426378041","title":"美国研究综述-芝加哥商品交易所集团、达尼莫尔科技公司、洲际交易所","url":"https://stock-news.laohu8.com/highlight/detail?id=2426378041","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426378041?lang=zh_cn&edition=full","pubTime":"2024-04-09 15:12","pubTimestamp":1712646726,"startTime":"0","endTime":"0","summary":"    路透社4月9日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括芝加哥商品交易所集团、丹尼默科技公司和洲际交易所。* 洲际交易所  ：杰富瑞将目标价从144美元上调至159美元             * 纳斯达克公司   ：杰富瑞将目标价从56美元上调至59美元             * Papa John's International Inc   ：Keybanc将目标价从84美元下调至78美元 以下是路透社周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419124937","title":"资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH，竞争对手却围追堵截","url":"https://stock-news.laohu8.com/highlight/detail?id=2419124937","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419124937?lang=zh_cn&edition=full","pubTime":"2024-03-15 04:09","pubTimestamp":1710446976,"startTime":"0","endTime":"0","summary":"    路透社3月14日 - Madrigal Pharmaceuticals公司的  药物成为第一个获得监管部门批准的 ，用于治疗一种以前被称为非酒精性脂肪性肝炎的严重类型的脂肪肝，因为开发一个数十亿美元市场的竞争正在加剧。在周四获得批准之前，该公司在开发这种疾病的治疗方法方面取得了有限的成功，这种疾病与肥胖密切相关，而且正在迅速蔓延。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419850046","title":"BUZZ-肝病药物在中期试验中达到主要目标，Ionis Pharma 公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2419850046","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419850046?lang=zh_cn&edition=full","pubTime":"2024-03-13 20:43","pubTimestamp":1710333820,"startTime":"0","endTime":"0","summary":"    3月13日 - ** Ionis Pharmaceuticals    股价盘前上涨3.29%至44.59美元 ** 该公司称 ，其实验性药物ION224已达到中期试验的主要目标，该药物被用于治疗一种被称为代谢功能障碍相关性脂肪性肝炎的脂肪肝。** MASH，以前称为非酒精性脂肪性肝炎 目前还没有获得批准的治疗方法** 美国食品和药物管理局正在审查竞争对手 Madrigal 制药公司的  药物，预计将于周四做出决定** 截至上一交易日收盘，股价年累计下跌约 15","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419047555","title":"艾奥尼斯制药公司的脂肪肝药物在中期试验中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2419047555","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419047555?lang=zh_cn&edition=full","pubTime":"2024-03-13 19:07","pubTimestamp":1710328056,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月13日 - Ionis Pharmaceuticals    周三表示，其治疗一种脂肪肝的实验性药物达到了中期试验的主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417239460","title":"美国研究综述-Arrivent 生物制药公司、弗格森公司、目标公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2417239460","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417239460?lang=zh_cn&edition=full","pubTime":"2024-03-06 14:48","pubTimestamp":1709707680,"startTime":"0","endTime":"0","summary":"    路透社3月6日 - 华尔街证券分析师周三调整了对 Arrivent Biopharma、Ferguson 和 Target 等几家美国上市公司的评级和目标价。要闻             * Arrivent Biopharma Inc   ：杰富瑞给予买入评级             * 弗格森  ：杰富瑞将目标价从 222 美元上调至 244 美元             * Target Corp   ：汇丰银行将其评级从 \"持有 \"上调至 \"买入\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414074158","title":"美国研究综述-Elf Beauty、Moderna、Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2414074158","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414074158?lang=zh_cn&edition=full","pubTime":"2024-02-26 15:57","pubTimestamp":1708934231,"startTime":"0","endTime":"0","summary":"    路透社2月26日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Elf Beauty、Moderna 和 Zscaler。要点             * 精灵美容公司  ：Piper Sandler将目标价从212美元上调至225美元             * Moderna   ：汇丰银行将目标价从持有下调至减持              * Zscaler Inc   ：摩根大通将目标价从212美元上调至240美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413796339","title":"Ionis Pharmaceuticals Inc2023财年实现净利润-3.66亿美元，同比减少35.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2413796339","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2413796339?lang=zh_cn&edition=full","pubTime":"2024-02-24 00:24","pubTimestamp":1708705484,"startTime":"0","endTime":"0","summary":"12月31日，Ionis Pharmaceuticals Inc公布财报，公告显示公司2023财年净利润为-3.66亿美元，同比减少35.56%；其中营业收入为7.88亿美元，同比增加34.24%，每股基本收益为-2.56美元。机构评级：截至2023年12月31日，当前有20家机构对Ionis Pharmaceuticals Inc目标价做出预测，其中目标均价为57.31美元，其中最低目标价为29.00美元，最高目标价为85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022400244681aef946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022400244681aef946&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413263298","title":"美国研究综述-模拟器件、Mosaic、Workday","url":"https://stock-news.laohu8.com/highlight/detail?id=2413263298","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413263298?lang=zh_cn&edition=full","pubTime":"2024-02-22 16:05","pubTimestamp":1708589139,"startTime":"0","endTime":"0","summary":"    路透社2月22日 - 华尔街证券分析师周四调整了对模拟器件、Mosaic 和 Workday 等几家美国上市公司的评级和目标价。* Nvidia Corp   ：BofA Global Research将目标股价从800美元上调至925美元              * Workday Inc   ：摩根大通将目标价从260美元上调至300美元  以下是路透社周四报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413420708","title":"嗡嗡声--美国股票走势-Toll Brothers、Natgas 公司、Eton 制药公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2413420708","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413420708?lang=zh_cn&edition=full","pubTime":"2024-02-21 23:55","pubTimestamp":1708530942,"startTime":"0","endTime":"0","summary":"        *      Eikon 个股走势搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      2月21日 - 华尔街周三下跌，因为投资者在等待芯片设计公司英伟达的高风险财报，如果财报不尽如人意，可能会阻碍今年的人工智能热潮。美东时间10:33，道琼斯工业平均指数  下跌0.24%，报38472.83点。标准普尔500指数  下跌0.26%，报4,962.55点；纳斯达克综合指数  下跌0.62%，报15,533.91点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413242314","title":"BUZZ-Ionis Pharmaceuticals 因第四季度收入超预期而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2413242314","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413242314?lang=zh_cn&edition=full","pubTime":"2024-02-21 21:36","pubTimestamp":1708522591,"startTime":"0","endTime":"0","summary":"    2月21日 - ** 制药商Ionis Pharmaceuticals    股价盘前上涨5.4%至46.75美元 ** 该公司公布的第四季度收入为3.25亿美元，超过分析师预计的1.7476亿美元--LSEG数据** 称2023年研发收入增至2.46亿美元，得益于其合作伙伴支付的里程碑款项，包括阿斯利康  支付的5,000万美元。** IONS预测2024年收入将超过5.75亿美元，而预期为6.3636亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412131839","title":"Ionis Pharmaceuticals Inc    预计每股亏损 83 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2412131839","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412131839?lang=zh_cn&edition=full","pubTime":"2024-02-19 22:37","pubTimestamp":1708353469,"startTime":"0","endTime":"0","summary":"   * Ionis Pharmaceuticals Inc     将于2月21日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。)   * LSEG 分析师对 Ionis Pharmaceuticals Inc 的平均预期是每股亏损 83 美分。* 华尔街对 Ionis Pharmaceuticals Inc 的 12 个月目标价中位数为 60.00 美元，高于其上次收盘价 44.43 美元。2月19日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2412972660","title":"美国研究综述-欧特克、Hireright Holdings、斑马技术公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2412972660","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412972660?lang=zh_cn&edition=full","pubTime":"2024-02-19 14:40","pubTimestamp":1708324852,"startTime":"0","endTime":"0","summary":"    路透社2月19日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 Autodesk、Hireright Holdings 和斑马技术公司。要闻             * 欧特克公司  ：贝伦贝格将目标价从250美元上调至290美元              * Hireright Holdings Corp   ：Needham将目标价从 \"买入 \"下调至 \"持有              * 斑马技术公司  ：Baird将目标价从292美元上调至312美元  以下是路透社周一报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411578065","title":"Ionis Pharmaceuticals Inc盘中异动 快速下挫5.06%报46.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411578065","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2411578065?lang=zh_cn&edition=full","pubTime":"2024-02-16 04:14","pubTimestamp":1708028089,"startTime":"0","endTime":"0","summary":"北京时间2024年02月16日04时14分，Ionis Pharmaceuticals Inc股票出现波动，股价大幅下挫5.06%。Ionis Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.46%。Ionis Pharmaceuticals Inc公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis广泛的临床和临床前产品链治疗多种疾病，重点是心血管、代谢、严重和罕见疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402160414497a43dc0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402160414497a43dc0e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2405150249","title":"Ionis(IONS.US)反义寡核苷酸疗法3期试验达主要终点 欧美上市申请递交在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2405150249","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2405150249?lang=zh_cn&edition=full","pubTime":"2024-01-23 09:48","pubTimestamp":1705974491,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月23日，Ionis Pharmaceuticals宣布其在研反义寡核苷酸疗法donidalorsen用于治疗遗传性血管水肿患者的3期OASIS-HAE研究获得积极结果。该疗法达主要终点，可显著降低患者HAE发作比率。Ionis计划在年中时于医学会议上公布该试验详细结果。Donidalorsen在试验中表现出了良好的安全性和耐受性特征，在接受donidalorsen治疗的患者中没有发生严重不良事件。此外，Donidalorsen获美国FDA授予孤儿药资格，在欧盟的孤儿药资格正在审评中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1059511.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2405979703","title":"BUZZ-遗传病药物在后期研究中获得成功，Ionis Pharma 公司业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2405979703","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2405979703?lang=zh_cn&edition=full","pubTime":"2024-01-22 20:43","pubTimestamp":1705927403,"startTime":"0","endTime":"0","summary":"    1月22日 - ** Ionis制药公司  股价盘前上涨2%，报52美元     ** 该公司的实验性药物多尼多生在治疗一种罕见且危及生命的遗传性疾病方面达到了 。)** 患者每四周或每八周接受一次80毫克剂量的皮下注射治疗** HEA会导致皮肤、胃肠道、上呼吸道系统、面部和咽喉出现不可预测和频繁的严重肿胀** 公司正准备根据研究结果向美国 FDA 提交上市申请     ** 截至上次收盘，IONS今年的股价下跌了3.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2405418975","title":"Ionis Pharma 的遗传病药物在后期研究中获得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2405418975","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2405418975?lang=zh_cn&edition=full","pubTime":"2024-01-22 20:09","pubTimestamp":1705925347,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透1月22日 - Ionis Pharmaceuticals    周一表示，其治疗一种罕见遗传病的疗法在一项后期试验中达到了主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404583124","title":"美国研究综述-苹果公司、Crane Nxt、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2404583124","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404583124?lang=zh_cn&edition=full","pubTime":"2024-01-18 20:06","pubTimestamp":1705579600,"startTime":"0","endTime":"0","summary":"    路透1月18日 - 华尔街证券分析师周四调整了对苹果公司、Crane Nxt 和 Netflix 等多家美国上市公司的评级和目标价。* Crane Nxt Co   ：D.A. Davidson将目标价从75美元上调至80美元  * Masonite International Corp   ：摩根大通将目标价从 115 美元上调至 120 美元  * Netflix Inc   ：Piper Sandler 将目标价从 400 美元上调至 475 美元              * Spirit Airlines Inc   ：花旗集团将其评级从 \"中性 \"下调至 \"卖出\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404522378","title":"美国研究综述-第一银行、Crane Nxt、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2404522378","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404522378?lang=zh_cn&edition=full","pubTime":"2024-01-18 14:52","pubTimestamp":1705560778,"startTime":"0","endTime":"0","summary":"    路透1月18日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括 Bank First、Crane Nxt 和 Netflix。要闻             * 第一银行  ：Piper Sandler将目标价从88美元上调至93美元              * Crane Nxt Co   ：D.A. Davidson将目标价从75美元上调至80美元              * Masonite International Corp   ：摩根大通将目标价从 115 美元上调至 120 美元              * Netflix Inc   ：Piper Sandler 将目标价从 400 美元上调至 475 美元              * Pinnacle Financial Partners Inc   ：Truist Securities将目标价从100美元下调至93美元  以下是路透周四报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404034819","title":"Ionis Pharmaceuticals Inc盘中异动 股价大跌5.04%报50.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2404034819","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2404034819?lang=zh_cn&edition=full","pubTime":"2024-01-17 03:03","pubTimestamp":1705431801,"startTime":"0","endTime":"0","summary":"北京时间2024年01月17日03时03分，Ionis Pharmaceuticals Inc股票出现异动，股价快速下跌5.04%。截至发稿，该股报50.84美元/股，成交量47.5982万股，换手率0.33%，振幅4.21%。Ionis Pharmaceuticals Inc股票所在的生物技术行业中，整体跌幅为0.35%。Ionis Pharmaceuticals Inc公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis广泛的临床和临床前产品链治疗多种疾病，重点是心血管、代谢、严重和罕见疾病。2016 年，Ionis 与合作伙伴 Biogen 将治疗罕见神经肌肉疾病脊髓性肌萎缩症的 Spinraza 推向市场，2023 年 Biogen 又推出了 ALS 药物 Qalsody。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240117030322861cab45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240117030322861cab45&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":0.0072},{"period":"1month","weight":-0.0206},{"period":"3month","weight":-0.1731},{"period":"6month","weight":-0.0831},{"period":"1year","weight":0.1713},{"period":"ytd","weight":-0.173}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0299},{"period":"3month","weight":0.0417},{"period":"6month","weight":0.2257},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位，利用新药研发平台，公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台，公司可以用反义药物拓展自身及其合作伙伴的药物种类，满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物，使其成为关键的临床值转折点。公司发明并进行新药早期研究，然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值，如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO，正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.019969},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.021252},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.021038},{"month":4,"riseRate":0.333333,"avgChangeRate":0.019602},{"month":5,"riseRate":0.375,"avgChangeRate":-0.062165},{"month":6,"riseRate":0.75,"avgChangeRate":0.018378},{"month":7,"riseRate":0.75,"avgChangeRate":0.036004},{"month":8,"riseRate":0.625,"avgChangeRate":0.020782},{"month":9,"riseRate":0.5,"avgChangeRate":0.017352},{"month":10,"riseRate":0.125,"avgChangeRate":-0.044855},{"month":11,"riseRate":0.625,"avgChangeRate":0.116043},{"month":12,"riseRate":0.5,"avgChangeRate":0.010906}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}